Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 13;10:5151. doi: 10.1038/s41467-019-13086-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 5 — CR-31 translationally targets glucose uptake in PDA. a Levels of transcripts encoding glycolytic proteins in light (<3 ribosomes) or heavy (≥3 ribosomes) polysome fractions from N or KP organoids treated with 10 nM CR-31 for 1 h relative to vehicle. Data are mean +/− S.D. n = 6. b Immunoblot analysis of SLC2A6, ENOLASE 1, ENOLASE2, ENOLASE 3, and GAPDH in N and KP organoids upon vehicle or CR-31 treatment for 5 h. Vinculin, loading control. c Immunoblot analysis of SLC2A6, ENOLASE1, ENOLASE2, ENOLASE3, and GAPDH in patient-derived PDA lines upon vehicle or CR-31 treatment. VINCULIN, loading control. d Glucose concentration in media spent from KP organoids upon treatment with vehicle or CR-31. Data are mean +/− S.D., Student’s t-test, n = 3. *p < 0.05, compared to DMSO treatment at the same timepoint. e Representative ¹⁸F-FDG-PET images of pancreatic tumours from mice after 24 h of treatment with vehicle or CR-31. Top, coronal view; bottom, transverse view. f Tumour uptake plots comparing initial metabolic activity before and after treatment with vehicle or CR-31. Left, maximum standardized uptake value (SUV)_max of tumour. Right, ratio of (SUV)_max in tumour compared to muscles. Data are mean +/− S.D., Student’s t-test. n = 7, Vehicle; n = 8, CR-31. g Glucose uptake comparing Cas9-expressing murine PDA cell lines transduced with sgRNAs targeting the ROSA locus (sgROSA) or against different regions of the Slc2a6 gene (sgSlc2a6). Data are mean +/− S.D., normalized to cell numbers. Student’s t-test, n = 4. h ECAR was measured in equal numbers of Cas9-expressing primary murine PDA cell lines transduced with sgRNAs targeting the ROSA locus (sgROSA) or different regions of the Slc2a6 gene (sgSlc2a6). ECAR was measured following the addition of glucose, Oligomycin, and 2DG. Data are mean +/− S.D., n = 5. i ECAR was measured in equal numbers of Cas9-expressing KP organoids transduced with sgRNAs targeting the ROSA locus (sgROSA) or different regions of the Slc2a6 gene (sgSlc2a6). ECAR was measured following the addition of glucose, Oligomycin, and 2DG. Data are mean +/− S.D., n = 6. Source data are provided as a Source Data file